Myeloid Cell Surface Antigen CD33, CD33 Molecule Transcript, CD33 Antigen, Siglec-3, P67, FLJ00391, Sialic acid-binding Ig-like lectin 3, CD33, CD33 Molecule, CD33 Antigen (Gp67), SIGLEC3, Gp67, Sialic Acid Binding Ig-Like Lectin 3

KO Status

RenMab: In Vitro

RenLite: F0

Drug Information

Launched drug: 1
Drugs in clinical trials: 21
Latest Research Phase: Approved

Drug Name





Clinical Trials

Gemtuzumab ozogamicin

CDP-771, CMA-676, CL-555201, WAY-CMA-676, hP67.6-calicheamicin


Ucb Sa, Pfizer Inc

Leukemia, Leukemia, Myeloid, Acute

CD33xCD3 Bispecific Antibody (Y-mAbs Therapeutics)

Y-Mabs Therapeutics Inc



Phase 2 Clinical

C.H. Boehringer Sohn Ag & Co. Kg

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Anti-CD33 CAR-NK cell therapy (PersonGen Biomedicine)

Phase 2 Clinical

Leukemia, Myeloid, Acute


OXS-3550-TriKE, GTB-3550, OXS-3550, OXIS-3550, 161533-TriKE, 161533 TriKE

Phase 2 Clinical

University Of Minnesota, Oxis Biotech

Mastocytosis, Systemic, Myelodysplastic Syndromes, Leukemia, Mast-Cell, Leukemia, Myeloid, Acute

Lintuzumab Ac-225 (Actinium Pharmaceuticals)

225Ac-HuM-195, HuM195-Ac-225, AC225-MOAB-M195

Phase 2 Clinical

Pdl Biopharma

Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes, Myeloproliferative Disorders, Multiple Myeloma, Leukemia, Myeloid, Acute

CART-33 (Chinese PLA General Hospital)

Phase 2 Clinical

Pla General Hospital

Leukemia, Myeloid, Acute



Phase 1 Clinical

Gemoab Monoconals

Leukemia, Myeloid, Acute


JNJ-67571244, JNJ-67371244, JNJ-1244

Phase 1 Clinical

Johnson & Johnson

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Anti-CD33 chimeric antigen receptor T cell therapy (Intrexon/ZIOPHARM Oncology)

Phase 1 Clinical

Ziopharm Oncology, Intrexon Co

Leukemia, Myeloid, Acute





Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells

Simmons D., Seed B.,

J. Immunol. 141:2797-2800(1988)

Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new siglec pseudogenes

Yousef G.M., Ordon M.H., Foussias G., Diamandis E.P.,

Gene 286:259-270(2002)

A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing

Hernandez-Caselles T., Martinez-Esparza M., Perez-Oliva A.B., Quintanilla-Cecconi A.M., Garcia-Alonso A., Alvarez-Lopez D.M., Garcia-Penarrubia P.,

J. Leukoc. Biol. 79:46-58(2006)

Complete sequencing and characterization of 21,243 full-length human cDNAs

Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Sugano S.,

Nat. Genet. 36:40-45(2004)

Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells

Vitale C., Romagnani C., Falco M., Ponte M., Vitale M., Moretta A., Bacigalupo A., Moretta L., Mingari M.C.,

Proc. Natl. Acad. Sci. U.S.A. 96:15091-15096(1999)

Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2

Paul S.P., Taylor L.S., Stansbury E.K., McVicar D.W.,

Blood 96:483-490(2000)

Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells

Vitale C., Romagnani C., Puccetti A., Olive D., Costello R., Chiossone L., Pitto A., Bacigalupo A., Moretta L., Mingari M.C.,

Proc. Natl. Acad. Sci. U.S.A. 98:5764-5769(2001)

Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling

Lajaunias F., Dayer J.M., Chizzolini C.,

Eur. J. Immunol. 35:243-251(2005)

Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression

Son M., Diamond B., Volpe B.T., Aranow C.B., Mackay M.C., Santiago-Schwarz F.,

Sci. Rep. 7:270-270(2017)

The Alzheimer's disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool

Siddiqui S.S., Springer S.A., Verhagen A., Sundaramurthy V., Alisson-Silva F., Jiang W., Ghosh P., Varki A.,

J. Biol. Chem. 292:15312-15320(2017)